These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24492372)

  • 1. Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis.
    Lanoix JP; Betoudji F; Nuermberger E
    Antimicrob Agents Chemother; 2014; 58(4):2316-21. PubMed ID: 24492372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice.
    Dutta NK; Karakousis PC
    Int J Antimicrob Agents; 2014 Dec; 44(6):564-6. PubMed ID: 25270632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
    Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.
    Bamrah S; Brostrom R; Dorina F; Setik L; Song R; Kawamura LM; Heetderks A; Mase S
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):912-8. PubMed ID: 25199004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection.
    Kaushik A; Ammerman NC; Tyagi S; Saini V; Vervoort I; Lachau-Durand S; Nuermberger E; Andries K
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.
    Marks SM; Mase SR; Morris SB
    Clin Infect Dis; 2017 Jun; 64(12):1670-1677. PubMed ID: 28329197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.
    Lanoix JP; Lenaerts AJ; Nuermberger EL
    Dis Model Mech; 2015 Jun; 8(6):603-10. PubMed ID: 26035868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial.
    Fox GJ; Nguyen CB; Nguyen TA; Tran PT; Marais BJ; Graham SM; Nguyen BH; Velen K; Dowdy DW; Mason P; Britton WJ; Behr MA; Benedetti A; Menzies D; Nguyen VN; Marks GB
    BMJ Open; 2020 Jan; 10(1):e033945. PubMed ID: 31900274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY; Lin CJ
    Indian J Tuberc; 2020 Dec; 67(4S):S16-S22. PubMed ID: 33308663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress in research of prophylactic therapy in contacts of rifampicin-resistant tuberculosis patients].
    Wang Z; Wang WJ; Ding XY; Lu P; Zhu LM; Liu Q; Lu W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Mar; 44(3):470-476. PubMed ID: 36942344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
    Arguello Perez E; Seo SK; Schneider WJ; Eisenstein C; Brown AE
    Clin Infect Dis; 2017 Nov; 65(12):2105-2111. PubMed ID: 29020308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
    Lanoix JP; Betoudji F; Nuermberger E
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates in the Treatment of Active and Latent Tuberculosis.
    Haas MK; Belknap RW
    Semin Respir Crit Care Med; 2018 Jun; 39(3):297-309. PubMed ID: 30071545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.
    Sterling TR; Njie G; Zenner D; Cohn DL; Reves R; Ahmed A; Menzies D; Horsburgh CR; Crane CM; Burgos M; LoBue P; Winston CA; Belknap R
    MMWR Recomm Rep; 2020 Feb; 69(1):1-11. PubMed ID: 32053584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
    Singh S; Gumbo T; Alffenaar JW; Boorgula GD; Shankar P; Thomas TA; Dheda K; Malinga L; Raj P; Aryal S; Srivastava S
    Int J Antimicrob Agents; 2023 Dec; 62(6):106968. PubMed ID: 37726063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.